Crizanlizumab, CAS 1690318-25-2

Product Description: Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease[1][2][3].

Applications: Neuroscience-Neuromodulation

Formula: N/A

References: [1]Hannah A. Blair, et al. Crizanlizumab: First Approval. Drugs. 80, 79-84 (2020). /[2]Ataga KI, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017 Feb 2;376(5):429-439. /[3]Ravirajsinh Jadeja, et al. Therapeutic potential of Crizanlizumab (anti-P-selectin) in improving sickle cell retinopathy in mice. Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4747.

CAS Number: 1690318-25-2

Molecular Weight: N/A

Compound Purity: 95.0

Research Area: Cardiovascular Disease

Solubility: H2O

Target: P-selectin

• Artikelnummer: MEXHY-P9987-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9987-10
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated